7-Year follow up of KEYNOTE 006: Pembrolizumab vs Ipilimumab in Advanced Melanoma

March 3, 2022

7-Year Follow-Up of KEYNOTE-006: Pembrolizumab Versus Ipilimumab in Advanced Melanoma presents results of seven years of follow-up of survival for participants enrolled in KEYNOTE-006, including those who consented to transition to the KEYNOTE-587 extension study (NCT03486873). 

It concludes that: 

  • After 7 years of follow-up, pembrolizumab continued to demonstrate improved OS compared with ipilimumab, with 7-year OS rates of 37.8% and 25.3%, respectively
    • Pembrolizumab continued to provide survival benefit, regardless of BRAF status, prior BRAFi therapy, and poor prognostic characteristics such as high LDH level, larger tumor size, or presence of brain metastase
    • For participants who completed ≥94 weeks of pembrolizumab with SD or better, 5-year PFS and OS rates were 70.1% and 92.9%, respectively
  • Second-course pembrolizumab showed additional antitumor activity in some participants
  • These results, which represent the longest follow-up from a phase 3 trial of immunecheckpoint inhibitor therapy for melanoma available to date, show that pembrolizumab continues to provide long-term OS benefit in participants with advanced melanoma, confirming pembrolizumab as a standard of care in this population

View the poster that was presented at the 18th International Congress of the Society for Melanoma Research on October 28-31 2021


« Back to News